Canton Hathaway’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Canton Hathaway’s Portfolio BHVN Stock Details BHVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-5,000	Closed	-$729K	–	264
2022 Q2	$729K	Sell	5,000 -860	-15%	-$110K	0.25%	48
2022 Q1	$695K	Buy	5,860 +200	+4%	+$24.9K	0.19%	57
2021 Q4	$780K	Buy	5,660 +1,160	+26%	+$148K	0.21%	62
2021 Q3	$625K	Hold	4,500	–	–	0.18%	73
2021 Q2	$437K	Hold	4,500	–	–	0.13%	77
2021 Q1	$308K	Sell	4,500 -370	-8%	-$29.9K	0.1%	90
2020 Q4	$417K	Buy	4,870 +370	+8%	+$31.4K	0.14%	75
2020 Q3	$293K	Buy	4,500 +1,800	+67%	+$118K	0.12%	76
2020 Q2	$197K	Buy	+2,700	New	+$144K	0.13%	68
2020 Q1	–	Sell	-3,000	Closed	-$163K	–	208
2019 Q4	$163K	Buy	3,000 +1,000	+50%	+$49.5K	0.08%	91
2019 Q3	$83K	Buy	+2,000	New	+$84.5K	0.05%	106

Other funds holding BHVN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

SFM

Soros Fund Management New York $9.12B AUM 30.69% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Canton Hathaway's BHVN Position: Q3 2022 in Review

Canton Hathaway sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q3 2022, closing a stake of 5,000 shares — an estimated $729K sold.

Canton Hathaway first reported a position in BHVN in Q3 2019 and held it in 11 quarters. The position peaked at $780K in Q4 2021. 240 funds tracked by Wall St. Rank hold BHVN as of Q3 2022.

Canton Hathaway reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q3 2022 after selling out during the quarter.
Canton Hathaway sold 5,000 Biohaven Pharmaceutical Holding Company Ltd. shares in Q3 2022, an estimated $729K.
Canton Hathaway first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q3 2019 and held it in 11 quarters.
Canton Hathaway's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $780K in Q4 2021.
240 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q3 2022.

Based on Canton Hathaway's 13F filing for Q3 2022, filed 17 Oct 2022.